The effects of co-administration of 3,4-methylenedioxymethamphetamine ("ecstasy") or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats

Neuroscience

Volumn 146, Issue 1, 2007, Pages 321-329

  Stanley, N ^a   Salem, A ^a   Irvine, R J ^a  

^a Discipline of Pharmacology   (Australia)

Author keywords

3; 4 methylenedioxymethamphetamine; hyperthermia; monoamine oxidase A inhibitor; neurotoxicity; para methoxyamphetamine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHOXYAMPHETAMINE; MOCLOBEMIDE; SEROTONIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BODY TEMPERATURE; CORPUS STRIATUM; ELECTROCHEMICAL ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE;

AMPHETAMINES; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; BODY TEMPERATURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DRUG COMBINATIONS; HALLUCINOGENS; HYDROXYINDOLEACETIC ACID; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TEMPERATURE; TIME FACTORS;

EID: 34247475702     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.01.012     Document Type: Article

References (57)

1. Alex K.D., Yavanian G.J., McFarlane H.G., Pluto C.P., and Pehek E.A. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55 (2005) 242-251
2. Ball K.T., and Rebec G.V. Role of 5-HT2A and 5-HT2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats. Psychopharmacology (Berl) 181 4 (2005) 676-687
3. Bexis S., Phillis B.D., Ong J., White J.M., and Irvine R.J. Baclofen prevents MDMA-induced rise in core body temperature in rats. Drug Alcohol Depend 74 (2004) 89-96
4. Blessing W.W., Seaman B., Pedersen N.P., and Ootsuka Y. Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J Neurosci 23 (2003) 6385-6391
5. Blessing W.W. Clozapine increases cutaneous blood flow and reduces sympathetic cutaneous vasomotor alerting responses (SCVARs) in rats comparison with effects of haloperidol. Psychopharmacology 181 (2005) 518-521
6. Brown P.L., and Kiyatkin E.A. Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. Eur J Neurosci 20 (2004) 51-58
7. Caldicott D.G., Edwards N.A., Kruys A., Kirkbride K.P., Sims D.N., Byard R.W., Prior M., and Irvine R.J. Dancing with "death": p-methoxyamphetamine overdose and its acute management. J Toxicol Clin Toxicol 41 (2003) 143-154
8. Callaghan P.D., Irvine R.J., and Daws L.C. Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry. Neurochem Int 47 (2005) 350-361
9. Chu T., Kumagai Y., DiStefano E.W., and Cho A.K. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51 6 (1996) 789-796
10. Cimbura G. PMA deaths in Ontario. CMAJ 110 (1974) 1263-1267
11. Colado M.I., Williams J.L., and Green A.R. The hyperthermic and neurotoxic effects of "ecstasy" (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115 7 (1995) 1281-1289
12. Colzi A., D'Agostini F., Cesura A.M., Borroni E., and Da Prada M. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J Pharmacol Exp Ther 265 (1992) 103-111
13. Dafters R.I., and Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") but not by fenfluramine. Psychopharmacology (Berl) 138 (1998) 207-212
14. Da Prada M., Kettler R., Keller H.H., Burkard W.P., Muggli-Maniglio D., and Haefely W.E. Neurochemical profile of moclobemide, a short acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248 (1989) 400-414
15. Darmani N.A., and Ahmad B. Long-term sequential determination of behavioral ontogeny of 5-HT1A and 5-HT2 receptor functions in the rat. J Pharmacol Exp Ther 288 1 (1999) 247-253
16. Daws L.C., Irvine R.J., Callaghan P.D., Toop N.P., White J.M., and Bochner F. Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry 24 (2000) 955-977
17. Degenhardt L., Barker B., and Topp L. Patterns of ecstasy use in Australia: findings from a national household survey. Addiction 99 (2004) 187-195
18. Eltayb A., Lindblom S., Oerther S., and Ahlenius S. Additive hypothermic effects of the 5-HT1A receptor agonist 8-OH-DPAT and the dopamine D2/3 receptor agonist 7-OH-DPAT in the rat. Acta Physiol Scand 172 (2001) 205-209
19. Esteban B., O'Shea E., Camarero J., Sanchez V., Green A.R., and Colado M.I. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl) 154 (2001) 251-260
20. Freedman R.R., Johanson C.E., and Tancer M.E. Thermoregulatory effects of 3,4-methylenedioxy-methamphetamine (MDMA) in humans. Psychopharmacology (Berl) 183 (2005) 248-256
21. Freezer A., Salem A., and Irvine R.J. Effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide. Brain Res 1041 (2005) 48-55
22. Gallardo-Godoy A., Fierro A., McLean T.H., Castillo M., Cassels B.K., Reyes-Parada M., and Nichols D.E. Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J Med Chem 48 (2005) 2407-2419
23. Gillman P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59 11 (2006) 1046-1051
24. Gordon C.J., Watkinson W.P., O'Callaghan J.P., and Miller D.B. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38 (1991) 339-344
25. Gough B., Imam S.Z., Blough B., Slikker Jr. W., and Ali S.F. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann N Y Acad Sci 965 (2002) 410-420
26. Gowing L.R., Henry-Edwards S.M., Irvine R.J., and Ali R.L. The health effects of ecstasy: a literature review. Drug Alcohol Rev 21 (2002) 53-63
27. Grahame-Smith D.G. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem 18 (1971) 1053-1066
28. Gudelsky G.A., and Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxy-methamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66 (1996) 243-249
29. Henry J.A., Jeffreys K.J., and Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340 (1992) 384-387
30. Herin D.V., Liu S., Ullrich T., Rice K.C., and Cunningham K.A. Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl) 178 (2005) 505-513
31. Irvine R.J., Keane M., Felgate P., McCann U.D., Callaghan P.D., and White J.M. Plasma drug concentrations and physiological measures in "dance party" participants. Neuropsychopharmacology 31 2 (2006) 424-430
32. Ishiwata T., Saito T., Hasegawa H., Yazawa T., Otokawa M., and Aihara Y. Changes of body temperature and extracellular serotonin level in the preoptic area and anterior hypothalamus after thermal or serotonergic pharmacological stimulation of freely moving rats. Life Sci 75 22 (2004) 2665-2675
33. Iurlo M., Leone G., Schilström B., Linnér L., Nomikos G., Hertel P., Silvestrini B., and Svensson H. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition. Psychopharmacology 159 (2001) 98-104
34. Jaehne E.J., Salem A., and Irvine R.J. Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation. Pharmacol Biochem Behav 81 (2005) 485-496
35. Kleven M.S., Assie M.B., and Koek W. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. J Pharmacol Exp Ther 282 2 (1997) 747-759
36. Lee T.F., Mora F., and Meyers R.D. Dopamine and thermoregulation: An evaluation with special reference to dopaminergic pathways. Neurosci Behav Rev 9 (1985) 589-598
37. Leonardi E.T., and Azmitia E.C. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10 (1994) 231-238
38. Lin M.T., Tsay H.J., Su W.H., and Chueh F.Y. Changes in extracellular serotonin in rat hypothalamus affect thermoregulatory function. Am J Physiol 274 (1998) R1260-R1267
39. Ling L.H., Marchant C., Buckley N.A., Prior M., and Irvine R.J. Poisoning with the recreational drug paramethoxyamphetamine ("death"). Med J Aust 174 (2001) 453-455
40. Malberg J.E., Sabol K.E., and Seiden L.S. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278 1 (1996) 258-267
41. Malberg J.E., and Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18 (1998) 5086-5094
42. Malpass A., White J.M., Irvine R.J., Somogyi A.A., and Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark agouti rats. Pharmacol Biochem Behav 64 (1999) 29-34
43. Mechan A.O., Esteban B., O'Shea E., Elliott J.M., Colado M.I., and Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") to rats. Br J Pharmacol 135 (2002) 170-180
44. Molloy A.G., and Waddington J.L. Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK & F 38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology (Berl) 92 (1987) 164-168
45. Moran D.S., Horowitz M., Meiri U., Laor A., and Pandolf K.B. The physiological strain index applied to heat-stressed rats. J Appl Physiol 86 (1999) 895-901
46. Nisijima K., Yoshino T., Yui K., and Katoh S. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 890 (2001) 23-31
47. Oie S., Guentert T.W., Tolentino L., and Hermodsson G. Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. J Pharm Pharmacol 44 (1992) 413-418
48. O'Shea E., Escobedo I., Orio L., Sanchez V., Navarro M., Green A.R., and Colado M.I. Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology 30 (2005) 1312-1323
49. Parrott A.C. MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50 (2004) 329-335
50. Parrott A.C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 20 2 (2006) 147-163
51. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd ed. (1986), Academic Press, Sydney
52. Saadat K.S., O'Shea E., Colado M.I., Elliott J.M., and Green A.R. The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ("ecstasy") when housed at high ambient temperature. Psychopharmacology (Berl) 179 (2005) 884-890
53. Scorza M.C., Carrau C., Silveira R., Zapata-Torres G., Cassels B.K., and Reyes-Parada M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem Pharmacol 54 (1997) 1361-1369
54. Shankaran M., and Gudelsky G.A. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl) 147 (1999) 66-72
55. Spanos L.J., and Yamamoto B.K. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 32 (1989) 835-840
56. Vuori E., Henry J.A., Ojanpera I., Nieminen R., Savolainen T., Wahlsten P., and Jantti M. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98 (2003) 365-368
57. Westerink B.H. Analysis of biogenic amines in microdialysates of the brain. J Chromatogr B Biomed Sci Appl 747 1-2 (2000) 21-32